Complete remission of a primary cutaneous follicle-center cell lymphoma (EORTC criteria)/diffuse large B-cell lymphoma (WHO criteria) by single first-line therapy with rituximab.
Nagasaka
Akiko
A
Matsue
Hiroyuki
H
Kawamura
Tatsuyoshi
T
Kanzaki
Mirei
M
Inozume
Takashi
T
Nakamura
Yuumi
Y
Shimzu
Akira
A
Shibagaki
Naotaka
N
Yanagi
Mitsuaki
M
Shimada
Shinji
S
D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D001365:Axilla / Q000473:pathology; D003937:Diagnosis, Differential; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D016393:Lymphoma, B-Cell / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis* / Q000188:drug therapy* / Q000473:pathology; D000069283:Rituximab; D012878:Skin Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab